Dermatomyositis Market

Global Dermatomyositis Market Size (2024 to 2029)

The global dermatomyositis market size is estimated to grow from USD 573.4 million in 2024 to USD 750.8 million by 2029, growing at a CAGR of 5.54% from 2024 to 2029.

MARKET DRIVERS

The growing prevalence of dermatomyositis worldwide primarily drives the global market growth.

The number of people suffering from dermatomyositis is growing rapidly worldwide with each year passing and this growing patient population highlights the need for effective treatments and management strategies, driving the demand for novel therapeutics and diagnostic instruments. In addition, researchers and pharmaceutical companies are concentrating on developing targeted therapies designed specifically to treat dermatomyositis. These targeted therapies seek to treat the disease's underlying immune system dysregulation and inflammation. The introduction of these novel therapies provides patients with new treatment options and promotes the global dermatomyositis market growth.

An increasing number of improvements in diagnostic methods further contribute to the dermatomyositis market growth.

Improved diagnostic techniques, such as immunohistochemistry and specific antibody testing, help differentiate dermatomyositis from other conditions with comparable symptoms. Imaging methods, like magnetic resonance imaging (MRI), help doctors determine a disease’s severity and monitor its response to treatment and these advancements allow for timely diagnosis and treatment planning.

The rising awareness about dermatomyositis among healthcare professionals and patients, advancements in diagnostic techniques for accurate and early detection of dermatomyositis, increasing healthcare expenditure, a growing number of improvements in infrastructure development, and a rising geriatric population that is more susceptible to dermatomyositis drive the market growth. The availability of reimbursement policies and insurance coverage for dermatomyositis treatment, expansion of research and development activities to develop novel therapeutics for dermatomyositis, technological advancements in treatment options, such as biologics and immunosuppressants and collaborations and partnerships between pharmaceutical companies and research institutions for drug development accelerates the market’s growth rate.

The growing investments in healthcare and dermatology research, increasing demand for personalized and targeted therapies for dermatomyositis, rising prevalence of autoimmune diseases, including dermatomyositis, rapid adoption of combination therapies for improved management of dermatomyositis and supportive government initiatives to promote rare disease research and treatment promotes the market growth. The development of biomarkers for accurate diagnosis and monitoring of dermatomyositis, growing focus on precision medicine and individualized treatment approaches, rising demand for non-invasive and minimally invasive treatment options for dermatomyositis, expansion of healthcare infrastructure in emerging economies and favorable reimbursement policies for dermatomyositis treatment further boost the growth rate of the dermatomyositis market.

MARKET RESTRAINTS

Limited understanding of the underlying causes and pathophysiology of dermatomyositis, poor awareness and delayed diagnosis of dermatomyositis, and limited treatment options for dermatomyositis, especially for refractory or severe cases, hamper the market growth. The high cost of dermatomyositis treatments and lack of affordable options limit access for some patients, and adverse effects associated with current treatment options, leading to suboptimal patient adherence and treatment discontinuation. Lack of standardized guidelines for the diagnosis and management of dermatomyositis, challenges in conducting clinical trials for dermatomyositis due to the rarity of the disease and the need for a diverse patient population and limited availability of specialized healthcare professionals with expertise in dermatomyositis management further impedes the market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Dermatomyositis Market Analysis By Type

The adult dermatomyositis segment is anticipated to account for the major share of the global market during the forecast period. Factors such as the higher prevalence of adult dermatomyositis compared to other types, the growing incidence of autoimmune diseases in the adult population, and the availability of more treatment options and therapeutic interventions for adult dermatomyositis drive segmental growth. The rising awareness and early detection of dermatomyositis in adults and higher research focus and investment in adult dermatomyositis due to its larger patient population further boost the growth rate of the adult dermatomyositis segment in the global market.

The JDMS segment is expected to capture a considerable share of the global market during the forecast period owing to the rising incidence of JDMS in children. Increased efforts in pediatric rheumatology research and understanding of JDMS, rising emphasis on early diagnosis and intervention in children with dermatomyositis and supportive organizations and foundations advocating for better treatment and management of JDMS contribute to the growth of the JDMS segment in the global market.

Global Dermatomyositis Market Analysis By Treatment Type

The immunosuppressive drugs segment is estimated to capture the leading share of the global market during the forecast period. High efficacy of immunosuppressive drugs in managing inflammation and controlling immune response in dermatomyositis patients, growing usage of immunosuppressive drugs due to their ability to suppress the immune system and reduce muscle inflammation primarily drive the segmental growth. Continuous research and development to improve the safety and efficacy of immunosuppressive drugs and growing clinical evidence supporting their use in managing dermatomyositis symptoms and preventing disease progression further boost the growth rate of the immunosuppressive drugs segment in the worldwide market.

The anti-inflammatory medication segment is expected to hold a considerable share of the global market during the forecast period owing to the growing usage of anti-inflammatory medication to manage inflammation and reduce muscle pain in dermatomyositis patients and the increasing availability of various anti-inflammatory drugs, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).

REGIONAL ANALYSIS

North America held the major share of the global market in 2023 and the domination of the North American region is predicted to continue throughout the forecast period. The growing prevalence of dermatomyositis in the North American region, the availability of advanced healthcare infrastructure and specialized treatment centers, and the increasing number of R&D activities in the field of dermatomyositis primarily drive the market growth in the North American region. The presence of key market players and pharmaceutical companies, favorable reimbursement policies for dermatomyositis treatment and growing awareness among healthcare professionals and patients about early diagnosis and treatment of dermatomyositis contribute to the North American market growth. The U.S. held the major share of the North American market in 2022 and is expected to continue to lead during the forecast period owing to the presence of leading pharmaceutical companies and advanced healthcare infrastructure.

APAC is expected to register the fastest CAGR among all the regions in the global dermatomyositis market during the forecast period. The growing awareness and diagnosis rates of dermatomyositis, increasing number of improvements in the healthcare infrastructure and access to advanced treatment options, growing healthcare expenditure and increasing number of initiatives for rare diseases from the governments of APAC countries drive the APAC market growth. Large population base, growing investments in research and development of novel therapies and increasing focus of multinational pharmaceutical companies in the region boost the growth rate of the APAC market.

Europe is a noteworthy regional market for dermatomyositis and is anticipated to occupy a substantial share of the worldwide market during the forecast period. Factors such as the rising prevalence of dermatomyositis in European countries, growing healthcare expenditure, increasing number of initiatives from the governments of European countries for rare diseases and advancements in diagnostic techniques and treatment options drive the European market growth. Collaborative efforts between research institutes, hospitals, and pharmaceutical companies, growing awareness among healthcare professionals and patients about dermatomyositis, and a favorable regulatory framework for drug approvals and clinical trials further boost the growth rate of the European market.

Latin America, Middle East and Africa are predicted to account for a moderate share of the global market during the forecast period.

KEY PLAYERS IN THE GLOBAL DERMATOMYOSITIS MARKET

Pfizer Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc. and Amgen Inc. are some of the major companies in the global dermatomyositis market.

RECENT HAPPENINGS IN THE MARKET

• In May 2023, according to a study. Dermatomyositis may benefit from CD38-targeted therapies. Anti-CD38 antibody daratumumab was used as a rescue therapy on a patient with MDA5-Positive Dermatomyositis with Interstitial Lung Disease. Pulmonary function improved after four 1,800 mg weekly injections.
• In March 2023, according to data presented as a late-breaker at the American Academy of Dermatology's annual meeting, results from a double-blind, placebo-controlled phase 2 trial using a monoclonal antibody targeting interferon beta (IFN-beta) showed significant improvements in skin lesions related to dermatomyositis.
• In March 2023, a significant portion of individuals with juvenile dermatomyositis, an uncommon but frequently severe and chronic systemic autoimmune disease, are resistant to treatment and require long-term immunosuppressive therapy. The use of the targeted biologic medication abatacept to treat these individuals has shown potential in small open-label research that was published in Arthritis and Rheumatology.
• In March 2023, a new study found that people with heart failure who also have polymyositis or dermatomyositis have a nearly double risk of cardiogenic shock and a more than double chance of death compared to those who do not have these disorders.

DETAILED SEGMENTATION OF THE GLOBAL DERMATOMYOSITIS MARKET INCLUDED IN THIS REPORT

This research report on the global dermatomyositis market has been segmented and sub-segmented based on type, treatment type, and region.

By Type

• Adult Dermatomyositis
• Dermatomyositis Sine Myositis
• Juvenile (Childhood) Dermatomyositis (JDMS)

By Treatment Type

• Anti-inflammatory Medication
• Immunosuppressive Drugs
• Immunoglobulin
• Others
  • Plasma Exchange
  • Monoclonal antibody
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa